Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease

Thyroid

Volumn 16, Issue 3, 2006, Pages 281-288

  Schmidt, Matthias ^a,b   Gorbauch, Eva ^a   Dietlein, Markus ^a   Faust, Michael ^a   Stützer, Hartmut ^b   Eschner, Wolfgang ^a   Theissen, Peter ^a   Schicha, Harald ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; RADIOACTIVE IODINE; TECHNETIUM 99M; THYROID ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ANTIBODY TITER; ARTICLE; AUTONOMOUS THYROID DISEASE; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOGENICITY; INCIDENCE; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RISK ASSESSMENT; THYROID DISEASE; THYROID SCINTISCANNING; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 33645522306     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.281     Document Type: Article

References (38)

1. Schicha H, Schober O 2003 Nuklearmedizin, Basiswissen und klinische Anwendung [Nuclear Medicine, Basic Knowledge and Clinical Application] 5. Auflage [5th edition] Schattauer-Verlag, Stuttgart, pp. 115-140.
2. Dietlein M, Dressler J, Grünwald F, Joseph K, Leisner B, Moser E, Reiners C, Rendl J, Schicha H, Schneider P, Schober O 2003 Guideline for in vivo- and in vitro procedures for thyroid diseases (version 2). Nuklearmedizin 42:109-115.
3. Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O 2004 Guideline for radioiodine therapy for benign thyroid diseases (version 3). Nuklearmedizin 43:217-220.
4. Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R, Schumm-Draeger PM 2004 Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96278 unselected employees. Thyroid 14:926-932.
5. Marine D, Lenhart CH 1911 Pathological anatomy of exophthalmic goiter. Arch Intern Med 8:265-316.
6. Charkes ND 1972 Graves' disease with functioning nodules (Marine-Lenhart Syndrome). J Nucl Med 13:885-892.
7. Vreden A, Klinser J, Rösler H, Lüscher D 1992 Immunogene Hyperthyreose als Komplikation nach Radioiodtherapie der nicht-immunogenen Hyperthyreose [Abstract]. Nuklearmedizin 31:A24.
8. Boddenberg B, Voth E, Schicha H 1993 Immunogene Hyperthyreose nach Radiojod-Ablation einer fokalen Autonomie [Immunogenic hyperthyroidism following radioiodine ablation of focal autonomy]. Nuklearmedizin 32:18-22.
9. Pilgrim S, Bähre M 1993 Hyperthyreose immunogener Genese nach Radioiodbehandlung einer Schilddrüsenautonomie. [Hyperthyroidism of immunogenic origin after radioiodine therapy of autonomous thyroid disease]. Akt Endokr Stoffw 14:123-126.
10. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohmer W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K, Vassart G, Usadel KH 1999 Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 84:90-97.
11. Kakinuma A, Morimoto I, Kuroda T, Fujihira T, Eto S, McLachlan SM, Rapoport B 1999 Comparison of recombinant human thyrotropin receptors versus porcine receptors in the thyrotropin binding inhibition assay for thyrotropin receptor autoantibodies. Thyroid 9:849-855.
12. Meller J, Jauho A, Hüfner M, Gratz S, Becker W 2000 Disseminated thyroid autonomy or Graves' disease: Reevaluation by a second generation TSH receptor antibody assay. Thyroid 10:1073-1079.
13. Zöphel K, Wunderlich G, Kopprasch C, Koch R, Franke W-G, Kotzerke J 2003 Predictive value of thyrotropin receptor antibodie using the second generation TRAb human assay after radioiodine treatment in Graves' disease. Nuklearmedizin 42:63-70.
14. Dunkelmann S, Rudolph F, Prillwitz A, Groth P, Schümichen C 1998 Paradoxe Effekte der Radiojodtherapie bei funktioneller Schilddrü senautonomie und milder Immunthyreopathie [Paradoxical effects of radioiodine therapy in functional thyroid autonomy and mild immunothyropathy]. Nuklearmedizin 37:17-22.
15. Dunkelmann S, Wolf R, Koch A, Kittner C, Groth P, Schuemichen C 2004 Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging 31:1428-1434.
16. Marinelli LD, Quimby EH, Hine GJ 1948 Dosage determination with radioactive isotopes. II. Practical considerations in therapy and protection. Am J Roentgenol Radium Ther 59:260-280.
17. Rubio IGS, Perone BH, Silva MNC, Knobel M, Medeiros-Neto G 2005 Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies. Thyroid 15:134-139.
18. Hirsch C, Spyra JL, Langhammer HR, Laubenbacher C, Senekowitsch-Schmidtke R, Schwaiger M 1997 Zum Auftreten einer Immunhyperthyreose nach Radiojodtherapie von Schilddrüsenautonomien [Prevalence of Graves' disease following treatment of autonomous goiter with I-131 therapy] Med Klinik 92:130-137.
19. Huysmans AK, Hermus RM, Edelbroek MA, Tjabbes T, Oostdijk, Ross HA, Corstens FH, Kloppenburg PW 1997 Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multifocal goiters. Thyroid 7:535-539.
20. 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 82:2926-2930.
21. Weiss M, Görges R, Hirsch C, Bader J, Tatsch K, Hahn K 1999 Auftreten einer immunogenen Hyperthyreose nach Radioiod-Therapie fokaler Schilddrüsenautonomien: Ergebnisse einer multizentrischen Erhebung [Immunogenic hyperthyroidism following iodine-131-therapy of non-immunogenic autonomous thyroid nodules: results of a multicenter evaluation]. Med Klinik 94:239-244.
22. Wallaschofski H, Müller D, Georgi P, Paschke R 2002 Induction of TSH-receptor antibodies in patients with toxic multifocal goiter by radioiodine treatment. Horm Metab Res 34:36-39.
23. Custro N, Ganci A, Scafidi V 2003 Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: Relation to thyroid autoimmunity. J Endocrinol Invest 26:106-110.
24. Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A 1994 Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre. Clin Endocrinol 40:803-806.
25. Regalbuto C, Salamone S, Scollo C, Vigneri R, Pezzino V 1999 Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma. J Endocrinol Invest 22:147-150.
26. Pollak L, Pilgrim S, Bähre M 1994 Immunogene Hyperthyreose nach Radioiodbehandlung einer Schilddrüsenautonomie [Abstract]. Nuklearmedizin 33:A43.
27. Weiss M, Mann K, Tatsch K, Kirsch CM 1994 Häufigkeit immunogener Hyperthyreosen nach Radio-Jod-Therapie von Schilddrüsenautonomien [Abstract]. Nuklearmedizin 33: A43.
28. Kat S, Becker W, Wolf F 1995 Häufigkeit von Immunthyreopathien nach I-131 Therapie von Schilddrüsenautonomien [Abstract]. Nucl-Med (Stuttgart) 34:A124.
29. Halfmann CE 1998 Die Entwicklung einer immunogenen Hyperthyreose nach Radioiodtherapie einer Schilddrüsenautonomie. Medizinische Dissertation [Thesis]. Universität zu Köln [University of Cologne].
30. Pedersen I, Knudsen N, Perrild H, Ovesen L, Laurberg P 2001 TSH-receptor antibody measurement for differentiation of hyperthyroidism in Graves' disease and in multifocal toxic goitre: A comparison of two competitive binding assays. Clin Endocrinol (Oxf) 55:381-390.
31. Cardia MS, Lima N, Knobel M, Medeiros-Neto G 2004 Evaluation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves' disease and other thyroid disorders. Thyroid 14:295-300.
32. Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P, Sanders J, Furmaniak J 2004 A new assay for thyrotropin receptor autoantibodies. Thyroid 14:830-835.
33. Wallaschofski H, Orda C, Georgi P, Miehle K, Paschke R 2001 Distinction between autoimmune and Non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multifocal goiter. Horm Metab Res 33:504-507.
34. DeGroot LJ. Radioiodine and immune system. Thyroid 1997; 7:259-264
35. Segundo C, Rodríguez C, Aguilar M, García-Poley A, Gavilán I, Bellas C, Brieva JA 2004 Differences in thyroid-infiltrating B lymphocytes in patients with Graves' disease: Relationship to autoantibody detection. Thyroid 14:337-344.
36. Monzani F, Del Guerra P, Caraccio N, Casolaro A, Lippolis PV, Goletti O 1997 arance of Graves' disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma. J Endocrinol Invest 20:294-298.
37. Verde G 1998 Graves' disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma. J Endocrinol Invest 21:334-335.
38. Freeman JS, Ertel NH, McA'Nulty JA, Khan MY 1998 Graves' disease following resection of autonomously functioning thyroid nodules. Two case reports. Minerva Endocrinol 23:53-56.